Chicago / Edinburgh
United States · NYSE American

Tarsier Pharma

Tarsier Pharma develops steroid-free therapies for autoimmune and inflammatory eye diseases.

Tarsier Pharma (Ticker: TARX US) develops steroid-free therapies intended to treat autoimmune and inflammatory diseases that affect the eyes. Its lead candidates, based on dazdotuftide, include TRS01 eye drops and TRS02 injectable therapy for non-infectious anterior uveitis and other inflammatory eye conditions. The offering consists entirely of primary shares, with no secondary shares stated; a 15% greenshoe option covers 750,000 additional shares.

The scheduled listing date on NYSE American was July 15, 2026. The proposed offering comprises 5,000,000 shares at an indicative price range of $8.00–10.00 per share. At the indicative range midpoint, the base offering would represent $45.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $294.00 million.

Konik Capital Partners, a division of T.R. Winston, is manager of the offering.

Prepared with IPOX® AI assistance. Information may contain errors.

Prepared with IPOX® AI assistance. Information may contain errors.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters